Hydrus Microstent
New findings ‘alter forever how we think of MIGS’ – Dr Ike Ahmed
Ivantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of ...
Alcon to acquire Hydrus Microstent MIGS device for AU$640 million
Multinational ophthalmic company Alcon has agreed to acquire privately-owned Californian firm Ivantis – and its Hydrus Microstent minimally invasive glaucoma ...
Ivantis to pay Glaukos US$60 million in MIGS patent settlement
MIGS device manufacturer Glaukos has reached an agreement with Ivantis over a patent infringement lawsuit regarding the latter’s Hydrus Microstent ...